1 Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021 Feb 1;42(5):373-498. 10.1093/eurheartj/ehaa612.
2 Gorenek B, Bax J, Boriani G, Chen SA, Dagres N, Glotzer TV, et al.; ESC Scientific Document Group. Device-detected subclinical atrial tachyarrhythmias: definition, implications and management-an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Europace. 2017 Sep;19(9):1556–78. 10.1093/europace/eux16328934408
3 Noseworthy PA, Kaufman ES, Chen LY, Chung MK, Elkind MS, Joglar JA, et al.; American Heart Association Council on Clinical Cardiology Electrocardiography and Arrhythmias Committee; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; and Stroke Council. Subclinical and Device-Detected Atrial Fibrillation: Pondering the Knowledge Gap: A Scientific Statement From the American Heart Association. Circulation. 2019 Dec;140(25):e944–63. 10.1161/ CIR.000000000000074031694402
4 Bayoumy K, Gaber M, Elshafeey A, Mhaimeed O, Dineen EH, Marvel FA, et al. Smart wearable devices in cardiovascular care: where we are and how to move forward. Nat Rev Cardiol. 2021 Aug;18(8):581–99. 10.1038/s41569-021-00522-733664502
5 Dagher L, Shi H, Zhao Y, Marrouche NF. Wearables in cardiology: here to stay. Heart Rhythm. 2020 May;17(5 5 Pt B):889–95. 10.1016/j. hrthm.2020.02.02332354455
6 Perez MV, Mahaffey KW, Hedlin H, Rumsfeld JS, Garcia A, Ferris T, et al.; Apple Heart Study Investigators. Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. N Engl J Med. 2019 Nov;381(20):1909–17. 10.1056/NEJMoa190118331722151
7 Healey JS, Alings M, Ha A, Leong-Sit P, Birnie DH, de Graaf JJ, et al.; ASSERT-II Investigators. Subclinical Atrial Fibrillation in Older Patients. Circulation. 2017 Oct;136(14):1276–83. 10.1161/CIRCULATIONAHA.117.02884528778946
8 Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, et al.; EMBRACE Investigators and Coordinators. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014 Jun;370(26):2467–77. 10.1056/NEJMoa131137624963566
9 Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, et al.; CRYSTAL AF Investigators. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014 Jun;370(26):2478–86. 10.1056/NEJMoa131360024963567
10 Kishore A, Vail A, Majid A, Dawson J, Lees KR, Tyrrell PJ, et al. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Stroke. 2014 Feb;45(2):520–6. 10.1161/STROKEAHA.113.00343324385275
11 Mahajan R, Perera T, Elliott AD, Twomey DJ, Kumar S, Munwar DA, et al. Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis. Eur Heart J. 2018 Apr;39(16):1407–15. 10.1093/eurheartj/ehx73129340587
12 Van Gelder IC, Healey JS, Crijns HJ, Wang J, Hohnloser SH, Gold MR, et al. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart J. 2017 May;38(17):1339– 44. 10.1093/eurheartj/ehx04228329139
13 Swiryn S, Orlov MV, Benditt DG, DiMarco JP, Lloyd-Jones DM, Karst E, et al.; RATE Registry Investigators. Clinical Implications of Brief Device-Detected Atrial Tachyarrhythmias in a Cardiac Rhythm Management Device Population: Results from the Registry of Atrial Tachycardia and Atrial Fibrillation Episodes. Circulation. 2016 Oct;134(16):1130–40. 10.1161/CIRCULATIONAHA.115.02025227754946
14 Botto GL, Padeletti L, Santini M, Capucci A, Gulizia M, Zolezzi F, et al. Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. J Cardiovasc Electrophysiol. 2009 Mar;20(3):241–8. 10.1111/j.1540-8167.2008.01320.x19175849
15 Svendsen JH, Diederichsen SZ, Højberg S, Krieger DW, Graff C, Kronborg C, et al. Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial. Lancet. 2021 Oct;398(10310):1507–16. 10.1016/S0140- 6736(21)01698-634469766
16 Lopes RD, Alings M, Connolly SJ, Beresh H, Granger CB, Mazuecos JB, et al. Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub- Clinical Atrial Fibrillation (ARTESiA) trial. Am Heart J. 2017 Jul;189:137–45. 10.1016/j.ahj.2017.04.00828625370
17 Kirchhof P, Blank BF, Calvert M, Camm AJ, Chlouverakis G, Diener HC, et al. Probing oral anticoagulation in patients with atrial high rate episodes: rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. Am Heart J. 2017 Aug;190:12–8. 10.1016/j.ahj.2017.04.01528760205